Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014
LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014
Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014
Summary
Global Markets Direct's, 'Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014', provides an overview of the Cerebral Infarction (Brain Infarction)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction) and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cerebral Infarction (Brain Infarction)- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cerebral Infarction (Brain Infarction) and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Cerebral Infarction (Brain Infarction) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Cerebral Infarction (Brain Infarction) pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Cerebral Infarction (Brain Infarction)- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Cerebral Infarction (Brain Infarction) pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipelineTable of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Cerebral Infarction (Brain Infarction) Overview 6
Therapeutics Development 7
Pipeline Products for Cerebral Infarction (Brain Infarction) - Overview 7
Pipeline Products for Cerebral Infarction (Brain Infarction) - Comparative Analysis 8
Cerebral Infarction (Brain Infarction) - Therapeutics under Development by Companies 9
Cerebral Infarction (Brain Infarction) - Therapeutics under Investigation by Universities/Institutes 10
Cerebral Infarction (Brain Infarction) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cerebral Infarction (Brain Infarction) - Products under Development by Companies 13
Cerebral Infarction (Brain Infarction) - Products under Investigation by Universities/Institutes 14
Cerebral Infarction (Brain Infarction) - Companies Involved in Therapeutics Development 15
Johnson & Johnson 15
CIMAB S.A. 16
Shin Nippon Biomedical Laboratories, Ltd. 17
Aprogen, Inc. 18
Cerebral Infarction (Brain Infarction) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Autologous Bone Marrow Derived Mesenchymal Stem Cells - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
epoetin alfa - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CNTO-0007 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AP-102 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug For Cerebral Infarction - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Anti-HMGB1 Monoclonal Antibody - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cerebral Infarction (Brain Infarction) - Dormant Projects 34
Cerebral Infarction (Brain Infarction) - Discontinued Products 35
Cerebral Infarction (Brain Infarction) - Product Development Milestones 36
Featured News & Press Releases 36
May 08, 2014: FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients 36
Sep 28, 2012: Mitsubishi Tanabe Pharma And Kyowa Hakko File Joint Application For Time-window Extension Of Thrombolytic Agents Grtpa And Activacin 36
Sep 28, 2012: Two Pharma Companies File Joint Application With Ministry Of Health, Labour And Welfare For Time-window Extension Of Thrombolytic Agents 37
Apr 27, 2010: Asahi Kasei Pharma Announces Preliminary Results From Phase III Clinical Study Of AT-877 For Acute Cerebral Infarction 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40
List of Tables
Number of Products under Development for Cerebral Infarction (Brain Infarction), H1 2014 7
Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Products under Investigation by Universities/Institutes, H1 2014 14
Cerebral Infarction (Brain Infarction) - Pipeline by Johnson & Johnson, H1 2014 15
Cerebral Infarction (Brain Infarction) - Pipeline by CIMAB S.A., H1 2014 16
Cerebral Infarction (Brain Infarction) - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2014 17
Cerebral Infarction (Brain Infarction) - Pipeline by Aprogen, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Cerebral Infarction (Brain Infarction) - Dormant Projects, H1 2014 34
Cerebral Infarction (Brain Infarction) - Discontinued Products, H1 2014 35
List of Figures
Number of Products under Development for Cerebral Infarction (Brain Infarction), H1 2014 7Number of Products under Development for Cerebral Infarction (Brain Infarction) - Comparative Analysis, H1 2014 8Number of Products under Development by Companies, H1 2014 9Comparative Analysis by Clinical Stage Development, H1 2014 11Comparative Analysis by Early Stage Products, H1 2014 12Assessment by Monotherapy Products, H1 2014 19Number of Products by Top 10 Target, H1 2014 20Number of Products by Stage and Top 10 Target, H1 2014 21Number of Products by Top 10 Mechanism of Action, H1 2014 22Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23Number of Products by Top 10 Route of Administration, H1 2014 24Number of Products by Stage and Top 10 Route of Administration, H1 2014 25Number of Products by Top 10 Molecule Type, H1 2014 26Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
Companies Mentioned
Johnson & Johnson
CIMAB S.A.
Shin Nippon Biomedical Laboratories, Ltd.
Aprogen, Inc.
Read the full report:
Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
SOURCE ReportBuyer
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article